Taysha Gene Therapies (TSHA) Free Cash Flow (2020 - 2026)

Taysha Gene Therapies has disclosed Free Cash Flow across 7 years of filings, most recently posting -$40.9 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$40.9 million, down 82.61% year-over-year; the trailing twelve-month figure through Mar 2026 was -$112.3 million (down 34.16% YoY), and the FY2025 annual result was -$93.8 million, down 15.45% from the prior year.
• Free Cash Flow came in at -$40.9 million for Q1 2026 at Taysha Gene Therapies, down from -$27.4 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $12.4 million in Q4 2022 to a low of -$49.6 million in Q2 2022.
• The 5-year median for Free Cash Flow is -$21.8 million (2024), against an average of -$23.6 million.
• Across the five-year window, Free Cash Flow soared 137.17% in 2022 and tumbled 257.73% in 2023, its largest moves.
• Taysha Gene Therapies' Free Cash Flow stood at $12.4 million in 2022, then sank by 257.73% to -$19.6 million in 2023, then grew by 8.1% to -$18.0 million in 2024, then slumped by 52.6% to -$27.4 million in 2025, then slumped by 49.09% to -$40.9 million in 2026.
• The last three Free Cash Flow figures came in at -$40.9 million (Q1 2026), -$27.4 million (Q4 2025), and -$23.8 million (Q3 2025), per Business Quant data.